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Abstract: Epidemiologic and clinical changes in the HIV epidemic over time have presented a challenge to public health
surveillance to monitor behavioral and clinical factors that affect disease progression and HIV transmission. The Medical
Monitoring Project (MMP) is a supplemental surveillance project designed to provide representative, population-based
data on clinical status, care, outcomes, and behaviors of HIV-infected persons receiving care at the national level. We
describe a three-stage probability sampling method that provides both nationally and state-level representative estimates.
In stage-I, 20 states, which included 6 separately funded cities/counties, were selected using probability proportional to
size (PPS) sampling. PPS sampling was also used in stage-II to select facilities for participation in each of the 26 funded
areas. In stage-III, patients were randomly selected from sampled facilities in a manner that maximized the possibility of
having overall equal selection probabilities for every patient in the state or city/county. The sampling methods for MMP
could be adapted to other research projects at national or sub-national levels to monitor populations of interest or evaluate
outcomes and care for a range of specific diseases or conditions.

Keywords: HIV, sampling, representative, surveillance.
INTRODUCTION
The HIV epidemic is dynamic: during the years since the
first cases were reported, it has been characterized by both
epidemiological and clinical instability, as the disease spread
rapidly, infected different populations, responded to
treatment and was associated with a changing spectrum of
opportunistic illnesses. Surveillance is an essential element
in monitoring and planning responses to important diseases
with such characteristics, and that is certainly the case for
HIV. A challenge to public health is to determine how to
conduct such surveillance to best answer questions about the
status of the disease and its impact, given the changes that
have occurred in disease spectrum, populations affected, and
social correlates of the illness and its spread. Such
surveillance also is highly relevant to the challenges in
reforming the health care system. The comparative
effectiveness of systems for delivering acute, chronic and
preventive services is best understood in the context of the
care that is provided in the full breadth of settings and
*Address correspondence to this author at Emory University, Rollins School
of Public Health, Department of Epidemiology, 1518 Clifton Road NE,
Atlanta, GA 30322, USA; Tel: +1 404 727-8750; Fax: +1 404 712-8392;
E-mail: a.d.mcnaghten@emory.edu
1874-6136/12

systems, and to the full range of populations using such
services.
AIDS has been reportable throughout the United States
since the onset of the HIV epidemic, and both AIDS and
HIV have been reportable in recent years [1]. The resulting
core information is invaluable, but insufficient [2]. In
response, the Centers for Disease Control and Prevention
(CDC) has conducted a number of secondary surveillance
studies. These were generally unlinked medical record and
interview studies conducted in a relatively small number of
urban sites. Though these studies provided much clinical and
behavioral detail, they did not meet the growing need for
integrated, representative, population-based data on clinical
status, care, outcomes, and behaviors at the national level.
The Medical Monitoring Project (MMP) is a CDC-sponsored
supplemental surveillance project that is designed to meet
that need by combining interviews with medical record
abstractions from patients selected using nationally
representative scientific probability sampling.
In this paper we describe a sampling strategy that
provides both nationally representative estimates as well as
estimates at the state level. These state level estimates cover
virtually all large states as well as a sampling of smaller
states. The strategy outlined in this paper (to provide both
2012 Bentham Open
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national and selected state estimates) provides a
methodological model that may be applied to the study of
other low incidence diseases in the United States as well as
similar diseases in other countries. The sampling strategy
described is somewhat different from more traditional
probability sampling models for national estimates, where
typically, primary sampling units consist of individual
counties and metropolitan areas. However, the use of states
as primary sampling units was consistent with the funding
and data collection model. It also provided participating
states with the direct benefit of having the ability to obtain
valid state level estimates.

the HCSUS sample design in developing a nationally
representative probability sample of non-institutionalized
persons receiving outpatient care for HIV infection in the 50
United States, the District of Columbia and Puerto Rico.

Probability Sampling

The sample was selected in three stages. The overall
approach is to randomly select from the sampling frames at
each stage using probability proportional to size (PPS)
sampling at all but the last stage. This method sets the
selection probability for each unit according to the relative
size of that unit: the larger the unit, the greater the
probability of it being selected. This allows the calculation of
selection probabilities in the last stage such that the overall
probability of selection for each person in the sample is
similar. This is desirable because each participant’s data is
similarly weighted, which is the most efficient circumstance.

The Rationale
The goal of probability sampling is to generate unbiased
estimates by developing a sample that accurately represents
the whole target population rather than a subset selected
according to some sort of rule. A probability sample is one in
which each person in the target population has some
probability of selection and in which the probability of
selection is known for each person who is actually selected.
That is, no person of interest is excluded and the number of
people represented by each selected person is known.1
Because of its ability to represent an entire population of
interest, probability sampling is the method of choice for
producing valid and unbiased statistical estimates for large
populations and their subgroups.
Single Stage vs Multistage Probability Sampling
The simplest way of accomplishing a probability sample
is a one-step process, or one stage sampling, by making
random picks directly from a sampling frame containing a
complete and current listing of all the persons in the
population. However, this is impractical for most large
populations, because it would result in a geographically
dispersed sample which is difficult and expensive to
implement. In addition, a complete and current list of
population elements, such as HIV infected persons in care,
may not be available. Fortunately, the construction of such a
list is not required in order to develop a probability sample.
Sampling can be accomplished by constructing a probability
sample in stages, i.e., by making a series of random picks
from each of a hierarchical series of sampling frames (e.g.,
geographic areas, health care providers, patients); these picks
must be made in such a way that each selection is linked to a
selection made in the previous sampling stage by virtue of
having the frame for that pick be defined by the elements
included in the previous selection.
The HIV Cost and Services Utilization Study (HCSUS)
used a multistage probability sample of persons in care for
HIV disease in the 48 contiguous United States in 1996,
demonstrating that such an approach is feasible for studying
HIV disease [3]. In the HCSUS, the hierarchy was as
follows: 1) participants were selected from a complete list of
patients being cared for by their provider, 2) providers were
selected from a complete list of providers in their area, and
3) areas were selected from a complete list of all such areas
in the United States. The MMP uses many of the features of
1

The inverse of the probability of selection for a sampled person is the
number of persons in the population represented by that sampled person.

THE STRATEGY FOR DEVELOPMENT OF THE
PROBABILITY SAMPLE IN MMP
For MMP, the population of interest is defined as all
persons who are HIV-positive and have received any
medical care from a known outpatient provider of HIV care
during a specified period of time. We refer to this time
period as the Population Definition Period (PDP).

The stage-I sampling frame consisted of 52 primary
sampling units (PSUs): the 50 United States, the District of
Columbia, and Puerto Rico. Twenty of these 52 PSUs were
selected using geographic stratification and probabilities
proportional to the estimated number of persons living with
AIDS at the end of 2002. Eighty-one percent of all reported
AIDS cases had been reported from those areas. Stage-II
sampling frames were developed separately for the selected
PSUs using a variety of appropriate methods. Six cities or
counties reside within five of the 20 selected states but were
considered separately in stage II (because their funding for
HIV/AIDS surveillance activities, including MMP, is
separate from that of the states in which they are situated).
For these five states, the different funding areas may be
thought of as separate sampling strata, each with its own
second stage sampling frames. Thus, there are a total of 26
sampling strata, with corresponding frames. In each of these
selected areas or frames, local MMP staff developed a
comprehensive list of all outpatient facilities that manage
HIV patients.
An outpatient facility was defined as any hospital-based
or stand-alone clinic or health care facility, any group or
private practice, or any grouping of these entities in which
medical records or a medical record system is shared.
Emergency departments and inpatient facilities were
excluded from the facility sampling frames, and thus from
MMP. Second-stage sampling was random with the
probability of selection proportionate to size in 19 of the 20
PSUs and the 6 separately funded areas. In the other PSU
(Delaware), a census of 21 facilities was necessary to obtain
the minimum number of patients needed. Stage II resulted in
the selection of 25 to 68 (mean = 41) facilities in each state
or separately funded area.
The stage-III sampling frames were developed separately
for each of the selected facilities. Frames consist of
comprehensive listings of persons with known HIV infection
who made at least one visit to one or more of the sampled
facilities during the PDP. Selections were random and were
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performed in such a way as to maximize the possibility of
having equivalent overall probabilities of selection for every
patient in the project area (state or city/county), and with
overall sampling rates calculated to obtain 10,000 selections
overall and a minimum of 400 persons in each of the 20
PSUs.
This design ensures that each person in the population is
given a non-zero probability of selection into the sample. It
results in a valid probability sample because each element
(member) of the target population is associated with a unit
(facility) in the secondary sampling frame, and each of these
is associated with a PSU.
FIRST STAGE OF SAMPLING
In most multistage probability samples, the first stage
sampling units are defined so the resulting first stage sample
comprises 20% or less of the defined units. In MMP, the
percentage is much higher because there were a smaller
number of PSUs. The decision to define a small number was
driven largely by the MMP funding model. Under CDC
Program Announcement 04155, entities eligible to receive
funding for MMP were the 50 states, the District of
Columbia, Puerto Rico, and the six cities/counties that
receive separate funding for HIV/AIDS surveillance.
Identifying and Stratifying the Primary Sampling Units
The separately funded cities/counties are Chicago, IL;
Houston, TX; Los Angeles County, CA; New York City,
NY; Philadelphia, PA; and San Francisco, CA. The decision
not to directly pick these cities was driven by a secondary
goal of providing statewide data to participating state health
departments. This was accomplished by folding the six
cities/counties into the five states that contain them for the
purposes of first stage sampling only (i.e., not for purposes
of administering the project). This yielded 52 PSUs. The
decision to sample 20 of the 52 PSUs was made based on
funding availability and face validity rather than on any
statistical argument.
In MMP, a systematic sampling with a random start was
used to generate a random stratified proportional to size
sample. In order to improve the reliability of the final
sample, the PSUs were stratified into five groups - four
geographic and one by size, then ordered by the PSU’s
measure of size (MOS). The MOS is an estimate of the
number of persons in the population of interest that are
contained in each unit of a sampling frame. For the first
stage of MMP, the MOS were the CDC estimates of the
number of adults and children living with AIDS at the end of
2002, current as of November 24, 2003. Although the target
population for MMP is all persons diagnosed with HIV in
care in the US, at the time the first stage was developed,
there was no data system that collected information on HIV
infected persons in care. Therefore, the estimated number of
persons living with AIDS was used as a proxy measure of
PSU size.
The systematic sampling procedure was as follows. We
first created a list or pseudo-population of patients grouped
by PSUs, arrayed by stratum and size. For example, if the
largest PSU in the first stratum (PSU #1) had 1000 cases,
then patients 1 to 1000 would be labeled “PSU #1;” and if
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PSU #2 had 2130 cases, then patients 1001 to 3130 would be
labeled “PSU #2.”
Selecting the Sample of States
Selection proceeds by picking a random start at the
beginning of the list and then taking uniform steps forward
through it. In MMP, the initial pick was to be a patient in the
first 5% of the list with subsequent steps each being 5%
forward through the list; 5% having been chosen because we
wished to sample 20 PSUs. The PSU containing each patient
picked in this procedure is included. Since the steps each
contain 5% of the total cases, at least one step must fall
among the patients that represent any PSU that has more
than 5% of the total cases. These large PSUs are sampled
with certainty. The process is iterative. The cases in certainty
PSUs are removed, the step size recalculated based on the
number of available and required PSUs, and the additional
PSUs to be sampled with certainty are identified and
removed. The cycle repeats until no further PSUs were
sampled with certainty.
Describing the particular choices made in the MMP
sample will elucidate this approach. The total number of
cases, that is, the sum of the MOS, across all 52 PSUs was
384,070. Five percent of this total is 19,204. Thus any PSU
with at least 19,204 cases was to be sampled with certainty.
Four PSUs had at least this many cases: California, Florida,
New York, and Texas (Table 1).
We then excluded the four certainty PSUs, recalculated
the total number of cases, and redefined the criteria for PSUs
that would also be sampled with certainty. Sixteen PSUs
remained to be sampled from 48 remaining PSUs. So, any
PSU with at least 6.25%, or 12,473 of the remaining 199,569
cases, was to be sampled with certainty. Four PSUs had at
least this many cases: Georgia, Illinois, New Jersey and
Pennsylvania. Twelve PSUs remained to be sampled from
the remaining 44 PSUs. So, any PSU containing at least
8.3%, or 11,860 of the remaining 142,321 cases was to be
sampled with certainty. No PSUs contained this many cases,
so no further PSUs were sampled with certainty.
The remaining 12 PSUs were to be sampled PPS in a
stratified manner. This was accomplished by recreating the
list according to stratum and size as described above, using
the cases from the remaining 44 PSUs. Selecting randomly
from such as list results in a sample that is: a) PPS because
the proportion of entries that are grouped under a PSU
reflects the proportion of cases contained in that PSU, and b)
stratified because of the specific ordering.
We grouped the states into five strata: four based on
region and one that grouped together states with few cases.
The stratum of states with few cases was formed to minimize
how many PSUs with few cases were included. Sampling
cases from PSUs that contain very few cases is difficult and
expensive to implement, so we defined a stratum of “small”
PSUs in such a way that only one PSU would be sampled
from that stratum. Since 12 PSUs were to be sampled, a
stratum containing PSUs with close to but less than the
“step” value of 8.3% (11,860) of all cases would likely
contribute one PSU but could not contribute two or more to
the sample. To define this stratum, the smallest PSU was
chosen and PSUs were added from the list (taking the next
smallest and so on) until the total number of included cases
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was smaller than 11,860 but as large as possible. In this
manner, 18 PSUs containing 11,118 were chosen for the
small state stratum; adding the next smallest would have
resulted in 12,915 cases in this stratum.
The remaining 26 PSUs (defined as “medium” size) were
divided into four geographical strata based on the Census
definitions of geographic regions: the Northeast region
contained Census divisions New England and Middle Atlantic
(states: CT, MA); Midwest contained Census divisions East
North Central and West North Central (states: WI, MN, IN,
MO, MI, OH); South contained Census divisions South
Atlantic, East South Central and West South Central as well as
Puerto Rico (states: AR, OK, KY, MS, AL, TN, SC, LA, NC,
VA, DC, MD, PR); and West contained Census divisions
Mountain and Pacific (states: OR, NV, CO, AZ, WA).
The geographic strata were ordered: Northeast, Midwest,
South and West and then were followed by the small PSU
stratum to form the pseudo population list. Within each stratum,
the PSUs were ordered by size. In order to preclude possible
sampling periodicity by size, within Northeast the PSUs were
ordered smallest to largest; within Midwest largest to smallest;
within South smallest to largest; within West largest to smallest;
and within the small PSU stratum smallest to largest. The
sampling frame resulting from the determination of the certainty
picks, and from the stratification and ordering of the remaining
PSUs, is shown in Table 1.
PSUs eligible to be one of 12 picked by random PPS
selection are listed after the certainty PSUs, beginning with
Connecticut. As implied above, the initial pick had to be within
the first 8.3% or 11,860 cases. A random number of 0.878 was
chosen, thus identifying a random start of 0.878 x 11,860, or
10,413. Case number 10,413 is contained within Massachusetts,
which therefore was the first randomly selected PSU. Stepping
though the list at intervals of 11,860 resulted in the selection of
one state in the Northeast, two each in the Midwest and the
West, six in the South and, as anticipated, one from the
grouping of states with few cases. Areas with “Yes” in the
Sampled column in Table 1 comprise the final sample of states.
SECOND STAGE OF SAMPLING
The purpose of the second-stage sampling was to select
facilities within the project areas. Although 20 PSUs were
selected in the first stage of sampling, there were 26 project
areas, as noted above, including the six cities/counties that are
funded and administered separately in five of the 20 selected
PSUs.
A facility sampling frame was developed individually in
each of the 26 project areas. An eligible facility was defined as
one known to provide HIV care, which was defined as having
providers who prescribe antiretroviral therapy or order CD4 or
HIV viral load tests. Providers who referred patients to other
providers rather than managing their HIV medical care were not
included in the facility sampling frame.
Constructing the Facility Sampling Frame
A variety of sources were used to identify facilities
providing HIV care (including the number of individuals in
care at those institutions). These included the HIV/AIDS
Reporting System (HARS) databases, laboratory reporting
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databases and other local databases, including AIDS Drug
Assistance Program and Medicaid databases. The HARS was
the best source for identifying HIV care providers. It is the
current version of the reporting system that all states have
used for surveillance of new AIDS cases since 1985 and,
since at least 2005, all new cases of HIV infection [4,5]. In
2005, when the first facility sampling frames were
constructed, 18 of the 20 states conducting MMP had HIV
viral load and/or CD4 reporting of any value or of all tests
performed.
For the 2005 pilot data collection cycle, the following
types of facilities were included on the facility sampling
frame: outpatient and inpatient care facilities; Veterans
Administration facilities; and state or local prisons and jails
that met the definition of providing HIV care. The following
types of facilities were not included: emergency departments
(because they do not provide sufficient information on the
standard of care), HIV counseling and testing sites and
laboratories (which report HIV infection, but do not provide
medical care for HIV infection), Federal prisons, military
bases and institutions (project areas have no jurisdiction to
obtain their medical records), and pediatric facilities (unless
they provided HIV medical care to persons age 18 and
older).
For the 2007 and subsequent data collection cycles, two
other exclusions were made from the facility sampling frame
to focus predominately on patients receiving outpatient care.
It was decided not to include inpatient facilities or prisons or
jails on the facility sampling frame. Inpatient facilities were
excluded since they do not provide primary medical care for
HIV infection. HIV-infected patients could have interfaced
with inpatient care facilities for a variety of reasons. It would
be prohibitively difficult to recruit providers who do not
typically provide HIV care (but who may have prescribed
antiretroviral medications or ordered CD4 counts or HIV
viral load tests during the patient’s inpatient stay). In
addition, the likelihood of finding and recruiting patients
who had only one encounter with the provider at an inpatient
facility would be much lower than that for patients who have
an ongoing relationship with a regular HIV care provider. In
some instances, such as hospice or care in long term care
facilities, primary medical care is provided; however, this
care is different from outpatient care provided by other
facilities on the facility sampling frame. Prisons and jails as
providers of HIV care were excluded from the sampling
frame because these facilities are not able to be accessed in
all project areas due to Institutional Review Board (IRB) and
other issues.
Once the lists of facilities from HARS and each of the
supplemental sources were obtained, cleaned, and
standardized, they were combined into a single facility
sampling frame (FSF) for each project area, on which each
facility only appears only once. Any outpatient facility that
met the MMP facility definition and was a known provider
of HIV medical care during the recent time periods used for
each data source was eligible to be included on the
FSF.Facilities that had not seen a patient with HIV during
the time frame estimated patient loads (EPLs) were obtained
(i.e., they had an EPL of 0) were included on the FSF, but
patients were not sampled from these facilities.

HIV Probability Sampling Strategy

Table 1.
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Sampling Frame of States, with Region, Measure of Size, Stratum, and Sample Indicator

Area of Residence

Measure of Size

Region*

PSU Stratum Size

Sampled

NEW YORK

63412

NE

Large (certainty)

Yes

FLORIDA

41015

S

Large (certainty)

Yes

TEXAS

27358

S

Large (certainty)

Yes

CALIFORNIA

52716

W

Large (certainty)

Yes

NEW JERSEY

15485

NE

Large (certainty)

Yes

PENNSYLVANIA

15362

NE

Large (certainty)

Yes

ILLINOIS

13718

MW

Large (certainty)

Yes

GEORGIA

12683

S

Large (certainty)

Yes

CONNECTICUT

6579

NE

Medium

No

MASSACHUSETTS

8025

NE

Medium

Yes

OHIO

5978

MW

Medium

No

MICHIGAN

5395

MW

Medium

Yes

MISSOURI

4838

MW

Medium

No

INDIANA

3429

MW

Medium

Yes

MINNESOTA

1818

MW

Medium

No

WISCONSIN

1797

MW

Medium

No

ARKANSAS

1837

S

Medium

No

OKLAHOMA

1908

S

Medium

No

KENTUCKY

2150

S

Medium

No

MISSISSIPPI

2602

S

Medium

Yes

ALABAMA

3660

S

Medium

No

TENNESSEE

5639

S

Medium

No

SOUTH CAROLINA

5863

S

Medium

Yes

LOUISIANA

6902

S

Medium

No

NORTH CAROLINA

7128

S

Medium

Yes

VIRGINIA

7443

S

Medium

Yes

DISTRICT OF COLUMBIA

8234

S

Medium

No

PUERTO RICO

10560

S

Medium

Yes

MARYLAND

11798

S

Medium

Yes

WASHINGTON

4889

W

Medium

Yes

ARIZONA

4316

W

Medium

No

COLORADO

3465

W

Medium

No

NEVADA

2502

W

Medium

No

OREGON

2448

W

Medium

Yes

NORTH DAKOTA

47

MW

Small

No

WYOMING

91

W

Small

No

SOUTH DAKOTA

99

MW

Small

No

MONTANA

181

W

Small

No

VERMONT

236

NE

Small

No

ALASKA

252

W

Small

No

IDAHO

262

W

Small

No
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(Table 1) contd…..

Area of Residence

Measure of Size

Region*

PSU Stratum Size

Sampled

MAINE

492

NE

Small

No

NEW HAMPSHIRE

506

NE

Small

No

NEBRASKA

567

MW

Small

No

WEST VIRGINIA

599

S

Small

No

IOWA

686

MW

Small

No

RHODE ISLAND

1058

NE

Small

No

NEW MEXICO

1066

W

Small

No

UTAH

1085

W

Small

No

KANSAS

1113

MW

Small

No

HAWAII

1247

W

Small

No

DELAWARE

1531

S

Small

Yes

*NE = Northeast; S = South; MW = Midwest; W = West.

Facilities are sampled in the second stage in a manner
analogous to the PSUs in the first stage. To accomplish PPS
sampling at this stage, an EPL of adult HIV infected patients
in each facility was also needed on the frame. The EPL is an
estimate of the actual number of eligible patients that will be
seen at a facility during the PDP for a given data collection
cycle. In 2007, for each data source from which EPLs could
be derived, a 4 month EPL was created using the most recent
data from each data source as well as from facility contacts
to accurately reflect the patient load for the January 1
through April 30, 2007 PDP. Data were obtained either from
a data run or other record-based source or as a less precise
estimate, typically provided by facility staff. A matrix, or
table, of EPLs from each data source was constructed for all
eligible facilities, and this matrix was used to create the FSF,
which in turn was used to select facilities for the previous
data collection cycles. During this step, the quality of the
different EPLs obtained across the various data sources was
evaluated in order to determine, for each facility, which EPL
was the most accurate to use for facility sampling.
Facility Linkage
A sampled patient’s overall selection probability is the
product of the three stage-specific selection probabilities. It
is desirable that this overall probability of selection be
uniform. Such uniformity will result in greater statistical
efficiency because there would be minimal variation in point
estimates derived from the information that patients
contributed. The result is that confidence limits for estimates
derived from MMP data will thus be minimized. Facilities
with very low EPLs, or small facilities, are problematic in
this regard because achieving uniform selection probability
may require the selection of more patients than they actually
have. In MMP, this was handled by linking known small
facilities to larger ones to create linked ‘facilities’ with
combined EPLs that met or exceeded a minimum value.
Facilities designated as small were linked to one or more
other facilities so that the small facility is selected for the
sample only if the facilities to which it is linked also are
selected. The desired minimum EPL across each project area
ranges between 40 and 80, and depend in part on the

distribution of EPLs across the entire FSF for that project
area. Minimum values of 40 to 80 have been determined to
be optimal for selecting the facility sample across project
areas based on anticipated design effects and distributions of
facility sizes.
In project areas of large geographic size, or with
variations in facility attributes by region, this linkage was
performed within pre-specified sub-regions to facilitate
efficient use of project area resources during data collection,
as well as to ensure facilities from every sub-region were
selected.
Selecting the Facility Sample
Electronic files containing the FSF from each project
area were sent to CDC using the CDC’s Secure Data
Network (SDN). All files sent to CDC are stripped of
identifying information for each facility; facilities are
identified only by unique numeric facility identification (ID)
number, assigned by the project area. Facility ID numbers
for all project areas are made unique by adding a 4-digit
project area code in front of the assigned 4-digit facility ID
number. The number of facilities sampled in each project
area varied from 25 in Houston and Los Angeles to 68 in
California (Table 2). In Delaware a census of all 21 eligible
facilities was used as the second stage sample. In other
project areas, facilities were randomly sampled from among
all facilities on the FSF. In the five states containing
cities/counties that are separately funded for surveillance, a
larger number of facilities was sampled in the second stage
of sampling in order to provide more useful local data to the
separately funded areas. Specifically, separate samples of
facilities were selected within each of the six separately
funded cities/counties as well as elsewhere in those states.
Of the 828 facilities sampled and eligible, 582
participated. Because this was a strict probability sample, no
replacement facilities were sampled. Furthermore, in those
project areas with lower facility response rates the sample
size was not increased because of the strict probability
sampling protocol. This might be considered in future years.
Facility participation rates ranged from 65% to 100%, with a
median of 91.4%.
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Table 2.
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Facility and Patient Sample Sizes and Facility Response Rates
Area

# Facilities
Sampled

# Facilities Sampled
and Eligible

# Facilities
Participating*

% Facilities
Participating

Patient Sample
Size

CALIFORNIA (rest of state)

68

56

28

69.6

500

LOS ANGELES, CA

25

23

21

91.3

400

SAN FRANCISCO, CA

30

29

24

89.7

400

DELAWARE

21

20

18

90.0

400

FLORIDA

60

49

31

85.7

754

GEORGIA

49

35

25

91.4

400

ILLINOIS (rest of state)

43

34

19

70.6

100

CHICAGO, IL

41

26

19

92.3

400

INDIANA

41

39

23

94.9

400

MASSACHUSETTS

39

38

35

94.7

400

MARYLAND

44

32

19

78.1

348

MICHIGAN

53

40

31

87.5

401

MISSISSIPPI

46

38

23

100.0

400

NORTH CAROLINA

43

36

20

91.7

400

NEW JERSEY

35

20

11

65.0

500

NEW YORK (rest of state)

44

42

33

95.2

200

NEW YORK CITY, NY

34

30

25

83.3

800

OREGON

60

37

23

91.9

400

PENNSYLVANIA (rest of state)

32

26

21

100.0

100

PHILADELPHIA, PA

28

22

20

100.0

400

PUERTO RICO

34

22

17

95.5

400

SOUTH CAROLINA

31

16

14

93.8

400

TEXAS (rest of state)

47

40

27

85.0

400

HOUSTON, TX

25

20

13

65.0

400

VIRGINIA

46

24

18

91.7

400

WASHINGTON

40

34

24

79.4

400

TOTAL

1059

828

582

87.2

10503

Mean

87.4

Min

65.0

Max

100.0

Median

91.4

*Includes only facilities with patients sampled.

THIRD STAGE OF SAMPLING
In the third and final stage of sampling, within each
participating facility, eligible patients are sampled for
inclusion in MMP. Participants are sampled from lists of
patients seen at each facility during the PDP (i.e., January 1
through April 30 of the data collection year). The selection
of the patient sample is done in a manner that results in an
equal probability of selection method sample at the patient
level. This means that patients are sampled from each facility
with a third-stage sampling probability which, when

multiplied by the second-stage selection probability, results
in the same overall selection probability for every patient
selected in the project area.
Each patient sample is only used for one data collection
cycle. A new sample of patients is drawn from the
participating facilities in each data collection cycle.
HIV-infected patients who received all of their care from
emergency departments or inpatient facilities are excluded
from MMP, given that these facilities are excluded from the
FSF. For sampled patients, in addition to information
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regarding their outpatient care, information on visits to
emergency departments or inpatient facilities is also obtained
during interviews, and/or may be documented in medical
records.
Constructing the Patient Sampling Frame
At the end of the PDP, health department MMP staff
request a list from each sampled facility of all HIV-infected
adults who received medical care (defined as any visit to the
facility for medical care or prescription of medications,
including refill authorizations and immunizations) during the
PDP. Patients are eligible for inclusion on the patient
sampling frame if they were HIV infected, at least 18 years
of age at the beginning of the PDP, and received care at a
sampled and participating facility during the PDP.
Facilities construct patient lists using International
Classification of Diseases (ICD-9 or ICD-10) codes for
procedures, tests or prescriptions during the PDP, or in
smaller facilities by reviewing appointment logs.
Patients are eligible for selection only at their first
reported visit to the facility during the PDP to ensure that
multiple visits to the same facility do not lead to multiple
opportunities for selection. As facilities use different
mechanisms to identify eligible patients, the lists are not
unduplicated across facilities. To account for multiplicity multiple patient visits to different facilities during the PDP the interview includes questions about the number of
different facilities visited during the PDP to allow for the
adjustment of the multiplicity of probability of selection in
the weighting process. Without this, persons visiting more
facilities would have higher probabilities of selection which
could lead to estimation bias.
For each facility, the actual count of patients seen during
the entire PDP derived from a facility’s patient list will differ
from the selected best EPL used to construct the FSF. EPLs
were obtained for a 4-month period, which should closely
match the number of patients on the patient lists obtained for
the 4 month PDP.
Selecting the Patient Sample
Patient sampling is conducted as soon as all patient lists
have been received from the participating facilities. The file
containing lists of HIV-infected patients seen during the PDP
at all participating facilities is used to select the patient
sample. The selected participant ID numbers are returned to
the project area via the CDC’s SDN after patient sampling
has been completed; this set of participant IDs comprises the
entire patient sample for the project area.
It was determined that 400 is the minimum sample size
for a state to obtain total population estimates with an
acceptable level of precision (assuming a moderate design
effect [of between 2 and 4], or increase in variance of
estimates due to using a multistage sampling design). This
sample size was assigned to most of the states with the
lowest AIDS prevalence. Sample sizes for states with
moderate to high AIDS prevalence were determined based
on the distribution of cases among the 20 sampled states and
the 6 separately funded cities/counties in those states, in
order to achieve a national sample size of approximately
10,000. States that have large numbers of prevalent AIDS
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cases were allocated larger sample sizes (California 1300;
Florida 800; Illinois 500; New Jersey 500; New York 1000;
Pennsylvania 500; and Texas 800). These project area
sample sizes will allow national estimates at an acceptable
level of precision (assuming a moderate design effect) for
subpopulations as small as 5% of the total population of
interest. Table 2 outlines the patient sample size selected for
each MMP project area. Although patient sample sizes of
800 and 400 were selected for Florida and Maryland,
respectively, errors in the estimation of patient loads during
facility sampling frame construction resulted in reduced
patient sample sizes in these areas. Patient selection was
accomplished by systematic random sampling within
facility. Changes in the probability of selection by
oversampling in facilities with lower response rates were not
attempted in order to maintain a constant probability of
selection across all facilities in order to handle patient
multiplicity.
It should be noted that in all stages of selection, the
probability nature of the sample allows the computation of
required probabilities of selection for selected patients:
Probability of Selection (Patienti) = P1 x P2 x P3x M,
where
P1 = the probability of selection for the state
P2 = the probability of selection for the facility associated
with the ith selected patient
P3 = the probability of selection for the ith selected patient
within the facility containing the patient.
M = the number of facilities the patient reports visiting
during the population definition period.
PATIENT
RECRUITMENT
COLLECTION

AND

DATA

All patients selected for the sample should be recruited
for enrollment in MMP. Persons selected during third-stage
patient sampling may be offered enrollment through two
general recruitment processes: MMP project area staffcontact enrollment or facility-referred enrollment. The
recruitment strategy varies according to facility preference
and state or local project area IRB requirements.
For MMP staff-contact enrollment, facilities provide
project area MMP staff with contact information for patients
selected for recruitment. After obtaining patient contact
information, the MMP staff contact selected patients to
describe the project and offer enrollment. Scripts are used by
all project areas to ensure a standardized recruitment
approach within project areas. Patients who are eligible for
enrollment and agree to participate are scheduled for an
interview at a location that is convenient for the patient and
meets the need for patient privacy.
Patients recruited through facility-referred enrollment are
initially contacted by staff of the facility from which they
were sampled. This may be done by telephone, in person,
through chart insert and/or letter mailed from the facility. If
by telephone or in person, the facility staff describe the
project briefly and ask permission to provide contact
information to MMP staff so that enrollment can be
completed, or the facility staff ask the patient to contact the
MMP staff. If recruitment takes place via chart insert or

HIV Probability Sampling Strategy

letter, the documents will describe the project briefly and
will provide contact information to enable the participant to
reach MMP staff.
Patients who agree to participate and consent to the
interview are asked questions by a trained interviewer. The
interview includes questions about patients’ demographics,
access to health care (including antiretroviral therapy),
unmet needs for services, sexual behavior, drug and alcohol
use, use of prevention services, and health and well-being.
Following the interview, medical record abstraction is
conducted on all sampled patients. Information obtained
from medical charts by trained data abstractors includes
patient demographics, insurance status, AIDS-defining and
other illnesses, laboratory values, prescription of
antiretroviral and other medications, and evidence of
substance abuse. Many project area IRBs have determined
that this abstraction can be done for all sampled patients as
part of surveillance activities but in other project areas it can
be done only if the patient agrees as part of the consent
process.
DISCUSSION
The experience of MMP demonstrates that it is possible
to develop a credible national probability sample approach
for HIV-infected persons receiving medical care in the
United States. Unique challenges, such as the need to
identify all providers of HIV care in each project area and
the estimated number of patients each provider serves, were
met by state, city and county health departments working
through their existing surveillance systems and relationships
they have built with providers of HIV care over the years.
However, due to the size of the task of constructing facility
sampling frames, the voluntary nature of the project (which
allows providers and patients to refuse participation at any
stage), and IRB and individual facility constraints on patient
recruitment, project areas had varying success in
constructing facility and patient sampling frames and
recruiting sampled providers and patients in the 2007 pilot
year. As subsequent MMP data collection cycles have been
implemented, project areas have adopted best practices for
facility and patient sampling frame construction, as well as
provider and patient recruitment, which have resulted in
improved efficiency and response rates.
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of the project area (stage I), facility (stage II), and patient
(stage III) response rates. Achieving an overall response rate
of at least 80% is ambitious, particularly in a pilot year, and
may be difficult to achieve even once MMP is being
conducted at peak efficiency. Therefore, MMP has also
pursued a policy of collecting minimal data about each
patient sampled (sex, age, race/ethnicity, mode of exposure
to HIV, most recent CD4 count) using state or local HARS
data to allow for an effective non-response analysis.
However, in some cases project area IRBs have not allowed
this without patient permission, and some facilities have
been unwilling to provide patient information for sampled
patients who chose not to participate.
Despite these challenges we expect that MMP will be an
important step forward in providing nationally representative
statistics about HIV patients in care in the U.S. We also note
that there are several nationally representative surveys that
have achieved response rates below 80% and that still
produce estimates that are respected and used by the
scientific and policy communities. For example, the
coverage rate for the HCSUS was 68% [8], and the response
rate for the Behavioral Risk Factor Surveillance System, a
state-based system of random digit dialed telephone surveys
on health risk behaviors, has declined over the years; the
response rate in 2006 was approximately 51% [9]. Once
higher response rates are achieved, we could compare the
demographics of the sampled patients with the demographics
of persons living with HIV from the project area’s
HIV/AIDS
reporting
system
to
ascertain
the
representativeness of their sample.
The MMP model, or similar models, could be adapted to
enrolling and evaluating care and outcomes for a large range
of chronic diseases for which comparative effectiveness data
are desired. Sampling strategies can be adapted in response
to priority research questions at the national level, or smaller
geographic areas. Using such methods, it should be possible
to gain an understanding of clinical effectiveness in the
populations that are most relevant and most representative of
the reference populations of greatest interest to health policy.
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